Medicare
The AHA appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2020.
Senate Finance Committee leaders yesterday released the statutory text for the Prescription Drug Pricing Reduction Act of 2019 (S-2543), which closely mirrors the chairman’s mark that passed the committee in July.
The Centers for Medicare & Medicaid Services today issued final rules reducing some regulatory burdens for providers participating in the Medicare and Medicaid programs, and revising discharge planning requirements for hospitals, critical access hospitals and home health agencies.
House Democratic leaders today released the Lower Drug Costs Now Act, a bill that would make a series of changes to the Medicare program in an effort to lower the price of prescription drugs.
The Centers for Medicare & Medicaid Services should make its proposed Medicare bundled payment model for radiation oncology voluntary, delay the start date and “balance the risk versus reward equation much more appropriately,” AHA told the agency.
Rebates reduced the growth in Medicare Part D spending for brand-name drugs between 2011 and 2015, but spending for brand-name drugs with rebates still grew by $2 billion or over the five-year period
The AHA appreciates the opportunity to comment on the Centers for Medicare & Medicaid Services’ specialty care models proposed rule, and specifically on the radiation oncology (RO) model. As described in the proposed rule, the RO model would test whether prospective, bundled payments for 90-day…
The Medicare Payment Advisory Commission yesterday and today discussed a number of issues.
The Centers for Medicare & Medicaid Services today issued a final rule with comment period implementing additional program integrity requirements for health care providers and suppliers who participate in certain federal health insurance programs.